<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01508923</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1332</org_study_id>
    <nct_id>NCT01508923</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes</brief_title>
  <official_title>Effect of NNC 90-1170 on 24-hour Glucose and Hormonal Profiles, Gastric Emptying, and Fasting Gluconeogenesis in Type 2 Diabetic Subjects. A Double-blind, Placebo-controlled, Randomised, Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to determine the effect of NNC
      90-1170 (liraglutide) on glucose and hormonal profiles, fasting gluconeogenesis and insulin
      secretion in subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">February 2002</completion_date>
  <primary_completion_date type="Actual">February 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour glucose profiles after three fixed meals</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour insulin profiles after three fixed meals</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First phase insulin and maximal insulin secretory capacity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EGR (endogenous glucose release) expressed in mg/kg/min</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GNG (gluconeogenesis) expressed in mg/kg/min</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour glucagon profiles after three fixed meals</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour FFA (free fatty acids) profiles after three fixed meals</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-hour paracetamol profiles after two fixed meals</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-hour NNC 90-1170 profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment period 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days</description>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_label>Treatment period 2</arm_group_label>
    <other_name>NNC 90-1170</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days</description>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_label>Treatment period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Diet treated and/or subjects in monotherapy with max. 50 % of maximal dose of
             sulphonylurea (SU). In addition, subjects in treatment with metformin and/or
             repaglinide could be included

          -  Body Mass Index (BMI) maximum 35 kg/m^2

          -  Fasting plasma glucose 7-15 mmol/l, both inclusive

        Exclusion Criteria:

          -  Impaired liver function

          -  Impaired renal function

          -  Anaemia

          -  Cardiac disease

          -  Uncontrolled treated/untreated hypertension

          -  Recurrent major hypoglycaemia as judged by the Investigator

          -  Known or suspected allergy to trial product or related products

          -  Females of child bearing potential who are pregnant, breast-feeding or have intention
             of becoming pregnant or are not using adequate contraceptive measures

          -  Current treatment with thiazolidinediones or chronic daily use of insulin (more than 7
             days) within three months in the absence of intercurrent illness

          -  Loss of more than 400 ml blood during the three months prior to study start

          -  Allergy to paracetamol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ã…rhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004 May;53(5):1187-94.</citation>
    <PMID>15111485</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2012</study_first_submitted>
  <study_first_submitted_qc>January 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2012</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

